GE HealthCare 4Q Net Down, Co Sees 2024 Organic Revenue Growth
By Rob Curran
GE HealthCare Technologies' fourth-quarter net income fell 27% even as revenue rose, and the maker of medical machinery forecast growth in 2024 demand.
The Silver Springs, Md., maker of magnetic-resonance imaging scanners and other health-care machines, posted fourth-quarter earnings of $403 million, down from $554 million a year earlier. Per-share earnings from continuing operations fell to 88 cents a share from $1.21 a share.
Excluding certain one-off items, GE HealthCare posted adjusted earnings of $1.18 a share, topping the average Wall Street target of $1.07 a share, based on an analyst survey from FactSet.
Fourth-quarter revenue rose 5% to $5.2 billion, also surpassing the mean analyst estimate $5.09 billion, as tallied by FactSet. Imaging revenue rose 4% to $2.8 billion. Revenue from pharmaceutical diagnostics surged 25% to $591 million. Ultrasound revenue ticked down 1% to $944 million. Revenue at the patient-care solutions unit rose 5% to $827 million.
For 2024, GE HealthCare forecasts organic revenue growth, which excludes the impact of acquisitions and foreign-exchange, of 4%. The company booked 2023 revenue of $19.6 billion. The company projected adjusted earnings before interest and taxes margin in a range between 15.6% and 15.9%.
GE HealthCare expects 2024 adjusted EPS in the range of $4.20 to $4.35, reflecting a growth of 7% to 11% versus adjusted EPS of $3.93 for 2023. Analysts polled by FactSet expect $4.24
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
February 06, 2024 07:09 ET (12:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks